Hepion pharmaceuticals announces pricing of public offering

Edison, n.j., feb. 16, 2021 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("nash"), today announced the pricing of its underwritten public offering of 44,200,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $88.4 million before deducting underwriting discounts, commissions and other offering expenses. all of the shares of common stock are being offered by the company.
HEPA Ratings Summary
HEPA Quant Ranking